Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets

SIMPLE SUMMARY: Immune checkpoint therapies have significantly improved the survival of patients with metastatic melanoma, however approximately 50% of patients exhibit no response. Understanding the underlying clinical, pathologic and genetic factors associated with failed response to immunotherapi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Main Authors: Gide, Tuba N., Pires da Silva, Inês, Quek, Camelia, Ferguson, Peter M., Batten, Marcel, Shang, Ping, Ahmed, Tasnia, Menzies, Alexander M., Carlino, Matteo S., Saw, Robyn P. M., Thompson, John F., Scolyer, Richard A., Long, Georgina V., Wilmott, James S.
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8267740/
https://ncbi.nlm.nih.gov/pubmed/34202352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13133186
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares